Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A

BACKGROUND

Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis, from binding to its heterodimeric receptor. In the phase 2b PATHWAY study, tezepelumab significantly reduced annualized asthma exacerbation rates (AAERs) versus placebo, irrespective of baseline disease characteristics, and improved lung function and symptom control, in adults with severe, uncontrolled asthma. This

METHODS

In this

RESULTS

At baseline, NP+ patients had higher blood eosinophil counts, higher FeNO levels and higher serum IL-5 and IL-13 levels than NP- patients. Tezepelumab 210 mg reduced the AAER versus placebo to a similar extent in both NP+ and NP- patients (NP+, 75% [95% confidence interval (CI): 15, 93], n=23; NP-, 73% [95% CI: 47, 86], n=112). Patients treated with tezepelumab 210 mg demonstrated greater reductions in blood eosinophil count and levels of FeNO, IL-5 and IL-13 than placebo-treated patients, irrespective of NP status.

DISCUSSION

Tezepelumab reduced exacerbations and reduced type 2 inflammatory biomarkers in patients with and those without NP, supporting its efficacy in a broad population of patients with severe asthma.

Informations de copyright

© 2021 Emson et al.

Déclaration de conflit d'intérêts

CE, KS, ÅH and GC are employees of AstraZeneca and may have stock options in AstraZeneca. JC received grants from AstraZeneca during the conduct of the study, and has received grants and personal fees from Genentech, personal fees from Teva Pharmaceuticals, grants from Sanofi and personal fees from Vectura Group outside of the submitted work. JRP is an employee of Amgen Inc., and holds stock and stock options in Amgen Inc. JRP has patents US20180296669A1 and WO201819479A1, Treatment of Asthma with Anti-TSLP Antibody, pending. The authors report no other conflicts of interest in this work.